TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.

Caceres, Gisela; McGraw, Kathy; Yip, Bon Ham; Pellagatti, Andrea; Johnson, Joseph; Zhang, Ling; Liu, Kenian; Zhang, Lan Min; Fulp, William J; Lee, Ji-Hyun; Al Ali, Najla H; Basiorka, Ashley; Smith, Larry J; Daugherty, F Joseph; Littleton, Neil; Wells, Richard A; Sokol, Lubomir; Wei, Sheng; Komrokji, Rami S; Boultwood, Jacqueline; List, Alan F.
Proc Natl Acad Sci U S A; 110(40): 16127-32, 2013 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-24043769